Add Yahoo as a preferred source to see more of our stories on Google. Shares of Sarepta Therapeutics shed more than half their value Tuesday after federal regulators told the company its potential ...
The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition. DMD is a genetic ...
On Sept. 19, the Food & Drug Administration announced it had granted “accelerated approval,” a conditional stamp based on limited data, to Sarepta Therapeutics’ Duchenne muscular dystrophy treatment ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- A ...
CAMBRIDGE, MA--(Marketwired - Sep 26, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 96 from Study 202, a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results